STMicroelectronics and Alifax S.r.l have worked together on a rapid, cost-efficient portable solution that will be available from Alifax, for point-of-care molecular diagnostic detection using highly reliable real-time Polymerase Chain Reactions (PCR) to amplify genetic material (RNA and DNA) in patient samples.
Leveraging technology developed and licensed from ST, Alifax is manufacturing the Molecular Mouse, a small portable instrument that contains a broad range of ST components, including STM32 MCUs, sensors, amplifiers, and other devices. Connected to a PC, the Molecular Mouse uses medical reagents created by Alifax to manage the control and testing of multiple targets or samples on a tiny disposable cartridge, manufactured by ST using its high-volume Micro-Electro-Mechanical Systems (MEMS) semiconductor process technology. Test results are available in less than an hour.
“One crucial lesson from the current global pandemic is the importance of rapid, cost-efficient point-of-care testing that allows immediate remote diagnosis, and then, if necessary, patient isolation,” said Alessandro Cremonesi, Chief Innovation Officer, STMicroelectronics. “ST has been investing in its Real-Time PCR platform convinced that innovative semiconductor-based diagnostic solutions can positively impact our lives.”
“Leveraging our high-volume semiconductor-manufacturing technology and long-term leadership in microfluidics, we’ve developed a rapidly customizable, highly flexible cartridge and instrumentation platform that delivers rapid and precise point-of-care diagnostic results, which Alifax has used to respond almost immediately to present pandemic and future diagnostic needs,” added Benedetto Vigna, President Analog MEMS, and Sensors Group, STMicroelectronics.
ST has demonstrated its efficacy and efficiency to scale reliable, high-volume manufacturing of semiconductors and its expertise in microfluidics for more than 25 years. Moreover, roughly 10 years of proven success in developing MEMS-based Real-Time PCR technologies has now culminated in a product generation that Alifax has rapidly adapted to address the current global pandemic.
“Building on our passion for research and excellence in innovation, Alifax has established its strength in hematology and bacteriology for diagnostic purposes. By working closely with ST and combining its foundational microfluidic and other technology in the Molecular Mouse and our pathogen-specific assays, starting from a COVID-19 test, we’re ready to contribute to rapidly diagnosing, isolating, and ultimately stopping the spread of pathogens,” said Paolo Galiano, President Alifax.